Gastric cancer—molecular and clinical dimensions

摘要: Gastric cancer imposes a considerable health burden around the globe despite its declining incidence. The disease is often diagnosed in advanced stages and associated with poor prognosis for patients. An in-depth understanding of molecular underpinnings gastric has lagged behind many other cancers similar incidence morbidity, owing to our limited knowledge germline susceptibility traits risk somatic drivers progression (to identify novel therapeutic targets). A few (PLCE1) (ERBB2, ERBB3, PTEN, PI3K/AKT/mTOR, FGF, TP53, CDH1 MET) alterations are emerging some being pursued clinically. Novel gene targets (ARID1A, FAT4, MLL KMT2C) have also been identified interest. Variations approaches dependent on geographical region evident localized cancer-differences that driven by preferences adjuvant strategies extent surgery coupled philosophical divides. However, greater uniformity approach noted metastatic setting, an incurable condition. Having realized only modest successes, momentum building carrying out more phase III comparative trials, using biomarker-based patient selection strategies. Overall, rapid progress biotechnology improving can help new drug discovery. future prospects excellent defining subsets patients application specific therapeutics. challenges remain be tackled. Here, we review representative clinical dimensions cancer.